InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $14.860

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,049 Telix JV Entity Contract with Endocyte for Prostate Imaging 10 Apr 2018 9:34AM $0.580 $14.860 risen by 2,462.07%
$5,049 Update - prostate imaging program 28 Mar 2018 1:50PM $0.580 $14.860 risen by 2,462.07%
$5,049 Drug Master File for Prostate Imaging Product Filed with FDA 26 Mar 2018 8:40AM $0.590 $14.860 risen by 2,418.64%
$5,049 AGM Notice of Meeting and Proxy Form 15 Mar 2018 3:23PM $0.480 $14.860 risen by 2,995.83%
$5,049 Telix and Radboud University Medical Centre Collaboration 15 Mar 2018 8:28AM $0.480 $14.860 risen by 2,995.83%
$5,049 Appendix 3B - release of shares from mandatory escrow 6 Mar 2018 11:18AM $0.540 $14.860 risen by 2,651.85%
$5,049 Odile Jaume to lead Telix European Operations 1 Mar 2018 9:56AM $0.540 $14.860 risen by 2,651.85%
$5,049 Corporate Governance Statement 26 Feb 2018 8:10AM $0.510 $14.860 risen by 2,813.73%
$5,049 Appendix 4G - key to governance disclosures 26 Feb 2018 8:10AM $0.510 $14.860 risen by 2,813.73%
$5,049 Appendix 4E and 2017 Annual Report 26 Feb 2018 8:10AM $0.510 $14.860 risen by 2,813.73%
$5,049 Shareholder Update 21 Feb 2018 12:19PM $0.470 $14.860 risen by 3,061.70%
$5,049 Notification regarding release of restricted securities 9 Feb 2018 9:41AM $0.560 $14.860 risen by 2,553.57%
$5,049 Appendix 4C - December 2017 quarter 30 Jan 2018 9:54AM $0.570 $14.860 risen by 2,507.02%
$5,049 Telix establishes Japanese subsidiary 15 Jan 2018 12:52PM $0.615 $14.860 risen by 2,316.26%
$5,049 Summary of voluntary escrow arrangements 15 Jan 2018 12:41PM $0.615 $14.860 risen by 2,316.26%
$5,049 App 3B - shares released from ASX mandatory escrow 15 Jan 2018 8:31AM $0.620 $14.860 risen by 2,296.77%
$5,049 Notification regarding release of restricted securities 22 Dec 2017 2:12PM $0.613 $14.860 risen by 2,326.12%
$5,049 Renal Cancer Collaboration with Memorial Sloan Kettering 14 Dec 2017 8:35AM $0.610 $14.860 risen by 2,336.07%
$5,049 Manufacturing Partnership with JFE Engineering Corporation 13 Dec 2017 8:25AM $0.585 $14.860 risen by 2,440.17%
$5,049 Appointment of Dr Bernard Lambert 4 Dec 2017 8:26AM $0.620 $14.860 risen by 2,296.77%
$5,049 Becoming a substantial holder 20 Nov 2017 8:21AM $0.750 $14.860 risen by 1,881.33%
$5,049 Becoming a substantial holder 17 Nov 2017 12:11PM $0.755 $14.860 risen by 1,868.21%
$5,049 Becoming a substantial holder 16 Nov 2017 6:12PM $0.760 $14.860 risen by 1,855.26%
$5,049 Becoming a substantial holder 16 Nov 2017 4:59PM $0.760 $14.860 risen by 1,855.26%
$5,049 Becoming a substantial holder 16 Nov 2017 4:58PM $0.760 $14.860 risen by 1,855.26%

901 - 925 of 946 results

Page 37 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.